Target Name: ZFYVE9
NCBI ID: G9372
Other Name(s): Mothers against decapentaplegic homolog-interacting protein | SMADIP | zinc finger FYVE domain-containing protein 9 | Zinc finger FYVE-type containing 9, transcript variant 3 | Smad anchor for receptor activation | Receptor activation anchor | Novel serine protease | MADHIP | ZFYVE9 variant 3 | Madh-interacting protein | SARA | ZFYV9_HUMAN | PPP1R173 | MADH-interacting protein | Zinc finger FYVE domain-containing protein 9 (isoform 3) | MAD, mothers against decapentaplegic homolog interacting protein, receptor activation anchor | NSP | novel serine protease | Zinc finger FYVE domain-containing protein 9 | zinc finger FYVE-type containing 9 | zinc finger, FYVE domain containing 9 | hSARA | protein phosphatase 1, regulatory subunit 173 | smad anchor for receptor activation

ZFYVE9: A Potential Drug Target and Biomarker for Decapentaplegia

Decapentaplegia is a chronic and often progressive disease that affects about 10% of the population, characterized by the loss of motor and sensory function in both legs. This condition is a result of a deficiency in dopamine, a neurotransmitter that plays a crucial role in movement and sensation. The most common cause of decapentaplegia is dystrophin deficiency, which results in the progressive loss of dopamine-producing neurons in the spinal cord.

While several treatments have been developed to manage decapentaplegia, there is still a high demand for more effective and long-lasting treatments. ZFYVE9, a protein that is expressed in the spinal cord and has been shown to interact with dopamine-producing neurons, could be a promising drug target and biomarker for decapentaplegia.

ZFYVE9: The Mothers Against Decapentaplegic Homolog-Interacting Protein

ZFYVE9 is a protein that is expressed in the spinal cord and has been shown to interact with dopamine-producing neurons. It is a member of the馃槈 family, which is known for its role in the development and progression of neurodegenerative diseases. ZFYVE9 has been shown to promote the survival of dopamine-producing neurons in the spinal cord and to protect against neurotoxicity.

One of the unique features of ZFYVE9 is its ability to interact with the protein p21, which is a known dopamine-producing neuron-specific regulator. This interaction between ZFYVE9 and p21 suggests that ZFYVE9 may play a role in the regulation of dopamine production and its distribution in the brain.

In addition to its interaction with p21, ZFYVE9 has also been shown to interact with several other proteins that are involved in the development and progression of decapentaplegia. These include the transcription factor, NF-kappa-B, and the protein, p53.

The Potential Role of ZFYVE9 as a Drug Target

The potential role of ZFYVE9 as a drug target for decapentaplegia is based on several factors. First, ZFYVE9 has been shown to interact with dopamine-producing neurons, which suggests that it may play a role in the regulation of dopamine production. Second, ZFYVE9 has been shown to promote the survival of dopamine-producing neurons in the spinal cord, which suggests that it may have a positive impact on the survival and function of these neurons.

Furthermore, ZFYVE9 has been shown to interact with several other proteins that are involved in the development and progression of decapentaplegia. These interactions suggest that ZFYVE9 may play a role in the regulation of multiple cellular processes that are involved in the development of decapentaplegia.

The Potential Role of ZFYVE9 as a Biomarker

The potential role of ZFYVE9 as a biomarker for decapentaplegia is based on several factors. First, ZFYVE9 has been shown to interact with dopamine-producing neurons, which suggests that it may be a useful biomarker for the diagnosis and progression of decapentaplegia. Second, ZFYVE9 has been shown to promote the survival of dopamine-producing neurons in the spinal cord, which suggests that it may be a useful biomarker for the effectiveness of potential treatments for decapentaplegia.

Furthermore, ZFYVE9 has been shown to interact with several other proteins that are involved in

Protein Name: Zinc Finger FYVE-type Containing 9

Functions: Early endosomal protein that functions to recruit SMAD2/SMAD3 to intracellular membranes and to the TGF-beta receptor. Plays a significant role in TGF-mediated signaling by regulating the subcellular location of SMAD2 and SMAD3 and modulating the transcriptional activity of the SMAD3/SMAD4 complex. Possibly associated with TGF-beta receptor internalization

More Common Targets

ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202